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Background: Generally, oral immunotherapy (OIT) aims for daily administration. Recently, the
efficacy of treatment with OIT at a low dose has been reported. However, the optimal dose and the
evaluation of dose-dependent OIT outcome have not been described.
Methods: A multicenter, parallel, open-labeled, prospective, non-placebo controlled, random-
ized study enrolled 101 Japanese patients for treatment with OIT. We hypothesized that target
dose OIT would induce short-term unresponsiveness (StU) earlier than reduced dose OIT. StU was
defined as no response to 6200 mg whole egg, 3400 mg milk, and 2600 mg wheat protein, as
evaluated by oral food challenge after 2-week ingestion cessation. To compare the two doses of
OIT efficacy, the maximum ingestion doses during the maintenance phase of OIT were divided
into 100%-dose or 25%-dose groups against their target StU dose, respectively. A total of 51
patients were assigned to the 100%-dose group [hen's egg (HE) ¼ 26, cow's milk (CM) ¼ 13,
wheat¼ 12] and 50 to the 25%-dose group (HE¼ 25, CM ¼ 13, wheat¼ 12). Primary outcome was
established by comparing StU at 1 year. Secondary outcome was StU at 2 years and established by
comparing allergic symptoms and immunological changes.
Results: The year 1 StU rates (%) for the 100%- and 25%-dose groups were 26.9 vs. 20.0 (HE), 7.7
vs. 15.4 (CM), and 50.0 vs. 16.7 (wheat), respectively. The year 2 StU rates were 30.8 vs. 36.0 (HE),
7.7 vs. 23.1 (CM), and 58.3 vs. 58.3 (wheat), respectively. There were no statistically significant
differences in StU between years 1 and 2. The total allergic symptom rate in the 25%-dose group
was lower than that in the 100%-dose group for egg, milk, and wheat. Antigen-specific IgE levels
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http://doi.org/10.1016/j.waojou.2020.100463Conclusions: Reduced maintenance dose of egg OIT showed similar therapeutic efficacy to the
target dose. However, we were not able to clearly demonstrate the efficacy, particularly for milk and
wheat. Reducing themaintenance dose for eggs, milk, and wheat may effectively lower the symptoms
associated with their consumption compared to the target OIT dose. Furthermore, aggressive reduc-
tion of themaintenance dosemight be important for milk and wheat, compared to the 25%-doseOIT.
Trial registration: UMIN000009373, Multicenter Oral Immunotherapy for Hen's Egg, Cow's Milk,
and Wheat-Allergic Children at Outpatient Clinic.
Keywords: Food hypersensitivity, Immunotherapy, Dose-response relationship, DesensitizationINTRODUCTION An alternative strategy to enhance OIT safety is toFood allergy (FA) is a major health issue that has
been increasing at the global level.1 Based on a
national survey, Imai et al reported that hen's egg
(HE; 39.0%), cow's milk (CM; 21.8%), and wheat
(11.7%) represent the most frequent causative food
allergens in Japan.2 Accordingly, numerous reports
are available on oral immunotherapy (OIT) for HE,3–
5 CM,3,6–9 wheat,10–13 and peanut14–20 allergies.
Meanwhile, other studies21–23 have reported that
patients treated with OIT reached a state of
desensitization or sustained unresponsiveness (SU)
providing an overall improvement in their quality of
life. These breakthrough findings suggest that the
efficacy of OIT may be considered a beacon of
hope for patients with severe FA.
Initially, OIT aims for a daily tolerant dose that is
increased rapidly; however, it is difficult to prevent
adverse allergic reactionsduringOIT.24Thus, several
studies have attempted to address these issues using
modified OIT. For example, omalizumab
administration combined with OIT25 was used to
decrease adverse reactions, and sublingual
immunotherapy (SLIT) combined with OIT was used
to safely increase symptom threshold.26
Additionally, epicutaneous immunotherapy (EPIT)
offers another novel safe approach for increasing
the symptom threshold.27,28 Recently, OIT initiated
at a low dose has been used to improve the safety
of allergen ingestion for patients with severe egg,
milk, and peanut allergies.22,29–31 However,
particularly in children, OIT may cause stress over
long-term treatment in proportion to the amount of
ingested allergen.attempt to achieve tolerance for FA through admin-
istration of food allergens at low doses. This is
considered a worthwhile pursuit, considering that
little evidence32–34 is available regarding the ideal
maintenance dose for causative allergens during
OIT. In 2012, a comparison of dose-dependent OIT
for CM allergy was reported by Keet et al.32 The
authors found that 2 different maintenance doses
of CM OIT (1000 and 2000 mg) exhibit similar
effectiveness, although this efficacy was evaluated
in combination with SLIT. Furthermore, in 2017, an
evaluation of dose-dependent OIT for peanut al-
lergywas reportedbyVickery et al,.33demonstrating
that low dose peanut OIT (300 mg/day) achieved
similar SU to those achieved by high dose
(3000 mg/day) treatment. Similarly, in 2019, a
cross-over OIT for wheat allergy was reported by
Nowak-We
Î
grzyn et al.34 The patients in the two OIT
dose groups (1445 mg/day and 2748 mg/day)
achieved desensitization in a similar manner.
However, previous dose-dependent studies
described narrow dose-differences for CM and
wheat allergensduringOIT. In addition, to thebest of
our knowledge, no study has characterized the
optimal ingestion dose for HE allergens during OIT.
Thus, it remains uncertain whether SU can be ob-
tainedwith a lowerOIT dose, or whether target dose
OIT strongly induces SU. To clarify this issue, this
study compared 2 maintenance OIT doses, target
and lower doses, capable of inducing short-term
unresponsiveness (StU). Although traditional OIT
studies measured long SU up to 4–10 weeks after
cessation of therapy,4,16,25,26,32–34 we defined the
alternative outcome as StU after 2-week cessation
of OIT. This new approach to OIT can be applied to
Volume 13, No. 10, October 2020 3various cases of food allergens frequently present in
patients’ diets. Moreover, this study represents the
first description of applying four times dose-
differences of OIT outcomes for HE, CM, and wheat
capable of inducing unresponsiveness earlier in pa-
tients with moderate allergies; meanwhile the low




This was a randomized, prospective, non-
placebo controlled, multicenter, open-label, and
parallel-group study conducted in Japan. This
study included 9 allergy units in separate hospitals
and was supported by a statistician. The enroll-
ment period was from December 2012 to April
2014. The follow-up period extended to April
2016.
Inclusion criteria
Patients were assessed for eligibility based on
their positive objective and significantly subjective
symptoms for HE, CM, or wheat allergies at the
baseline oral food challenge (OFC) performed by
allergists. The inclusion criteria were: (1) patients of
3–15 years of age; (2) patients with positive OFC
test result within 3 months before the trial; and (3)
patients allergic to either HE, CM, or wheat.
All patients had supported their allergic sensi-
tization, as shown by serological antigen-specific
IgE of > 0.35 (kUA/L). A confirmatory skin prick
test was not performed. The immediate type of FA
was defined as having at least 1 or more objective
allergic symptoms such as obvious urticaria, re-
petitive cough, wheezing, emesis, and diarrhea, or
clinically significant subjective symptoms such as
throat pain, abdominal pain, and other changes in
activity, confirmed by OFC within 3 months before
the study, and evaluated by an allergist. The
thresholds for eliciting positive symptoms for HE,
CM, or wheat-allergic children were > 194 mg of
whole egg protein (one thirty-second amount of
scrambled egg) and  1550 mg (one quarter of a
scrambled egg); > 102 mg of milk protein (3 mL of
unheated milk) and  850 mg (25 mL of unheated
milk); or > 78 mg of wheat protein (1.5 g of boiled
pasta or 3 g of boiled udon noodle) and  650 mg
(12.5 g of boiled pasta or 25 g of boiled udonnoodle), respectively. These lower and upper limits
were set to reduce the risk of anaphylaxis in out-
patients while still ensuring statistically clear
differences.
Exclusion criteria
The exclusion criteria were: (1) patients with
absence of objective or significantly subjective
allergic symptoms (eg, only slight subjective
symptoms: temporary discomfort of the oral cavity,
throat, and abdomen) at the baseline OFC; (2)
patients who experienced anaphylaxis and were
treated with adrenaline injection at the baseline
OFC just before the trial (for safety reasons and to
make the differences in the outcome clear); (3)
patients with “not well-controlled” atopic derma-
titis, bronchial asthma, or any underlying disease;
(4) patients who had been treated with some other
immunotherapy (eg, SLIT, another OIT); or (5) pa-
tients with a developmental problem or mental
disorder (eg, restless patients, to reduce the risk of
exercise-induced anaphylaxis just after OIT inges-
tion at home). However, we did not exclude pa-
tients based on the level of antigen-specific IgE, or
past history of anaphylaxis.
Protocol for OIT
OIT target doses were defined as ingestion of
6200 mg of whole egg protein (a scrambled egg,
made using 50 g of raw egg), 3400 mg of CM
protein (100 mL of unheated milk), or 2600 mg of
wheat protein (50 g of boiled pasta or 100 g of
boiled udon noodle).35 The maximum ingestion
doses at the maintenance phase of OIT were
divided into the 100%-dose or 25%-dose groups
against their target StU dose. This target dose of
egg was similar to the full dose of OFC
(Table S1), with reference to the Japanese
pediatric guideline for FA.36 We utilized such a
large difference between groups to determine
whether different doses of a food allergen induce
StU. The target doses of CM and wheat were
decreased to nearly half the full dose. However, a
potential difficulty was identified for pre-school
children to ingest a half dose of raw milk or
wheat noodles during OIT. This was postulated to
affect the adherence to the OIT, as the patients
were requested to consume a large volume with
only small amounts of protein in the wheat noodles
and raw milk compared to scrambled eggs. For
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noodles are large of volumes for young children to
consume every day. Nevertheless, we did not
permit the patients to ingest alternate food options
(eg, milk cake) during the build-up phase in order
to avoid the inaccurate measurement of the caus-
ative foods by the parents. The only exception to
this, was for the wheat OIT, in which the patients
were allowed to consume alternative pasta or
bread foods that contained the same amount of
protein as the udon noodles, after reaching the
maintenance dose with permission of the
attending allergist.
The patients who consented to OIT were
randomly assigned to the 2 groups, initially at a 1:1
ratio (Fig. 1). The stratified factor of randomization
was the threshold of objective, and significantly
subjective, symptoms at baseline OFC. The
patients were asked to consume their respective
allergens daily at home. These causative foods
for OIT were purchased by the patients
themselves at the market. Patients used an
accurate scale that could measure 0.1–0.01 g of
scrambled egg or boiled udon noodle, or 0.1–
0.01 mL of unheated milk with guidance from the
medical doctors and dietitians. The ingestion
doses of OIT were gradually increased (Table S2)
at the outpatient clinic or at home, to a
maintenance dose if the allergic symptoms did
not occur for more than 5 consecutive days. A
total of 20 increasing dose levels were assignedFig. 1 Study protocol. OFC: oral food challenge. Patients consenting t
ingestion dose gradually increased, if the allergic symptoms did not oc
doses were defined as ingestion of 6200 mg of whole egg protein, 3400
and maintenance phase, the maximum dose ingestion in 100%-OIT gr
group was limited to 25% of the target dose. Build-up and maintenanc
causative food avoidance, OFC for short-term unresponsiveness was pfor the egg and 25 for the milk and wheat. For
asymptomatic individuals, a minimum of 100
days for the egg, and 125 days for the milk and
wheat was required to reach the maintenance
dose. The patients were advised to rest for more
than 1 h after OIT ingestion to reduce the risk of
exercise-induced adverse allergic reactions. The
gradual ingestion dose increase was halted or
decreased according to the severity of allergic
symptoms as needed. If moderate or severe
allergic symptoms (eg, Grade 2 or 3 in Table S3)
occurred, the ingestion dose was reduced until
no symptom occurred with ingestion. We
selected StU as the primary outcome in this study
rather than the typical SU for cessation 4–8
weeks. Patient StU was evaluated via open-label
OFC annually after a two-week avoidance of their
corresponding allergy-causing foods. The OFC for
StU evaluation was performed using the same
protocol in both the 100%-dose group and 25%-
dose group. These cumulative doses of OFC were
equal to 1 heated whole egg, 100 mL of unheated
milk, or 100 g of boiled udon noodle. These OFC
doses were also the same as the maximum of
100%-dose OIT. They were divided into 1/8, 3/8,
and 4/8 of the total dose per 30 min. Patients who
developed symptoms during OFC in the first year
were judged to have a desensitization status. They
continued their OIT for another year with informed
consent and underwent OFC again in the second
year. However, the patients who passed OFC were
deemed to have reached StU at 12 or 24 months.o oral immunotherapy were randomized into 2 groups. At-home-
cur for more than 5 consecutive days. (build-up; Y axis). OIT target
mg of CM protein, 2600 mg of wheat protein. During the build-up
oup was same as the target dose. The maximum dose in 25%-OIT
e phases occurred at outpatient clinics. After 2 weeks of complete
erformed at 12 and 24 months (X axis)
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not restricted for patients with other food allergies.
After completing the study, the patients who
reached StU with OIT were requested to consume
their target dose of causative food (“a few minutes
well-heated” scrambled eggs, raw milk, or boiled
wheat noodles) at least once per week at home.
They were also permitted to consume dairy prod-
ucts on other days to maintain their StU.37 They
were followed-up continuously by an allergist to
evaluate typical SU with longer avoidance, exer-
cise,38 or deconditioned status (eg, tiredness,
infection, and sickness).Study outcome
The primary endpoint was comparison of StU
rates between the 100%- and 25%-dose groups in
the first year. The secondary endpoints were: 1)
StU rate at year 2 of follow-up; 2) immunological
changes, which were measured every 6 months, in
antigen-sIgE for egg-white, ovomucoid, milk,
casein, wheat, and omega-5 gliadin, and antigen-
sIgG and antigen-sIgG4 for egg-white, ovomu-
coid, casein, wheat, and omega-5 gliadin; and 3)
rates of allergic symptoms and medication used
during OIT ingestion for 2 years.Allergic reactions and treatments
Before beginning OIT, all patients received
training for management of adverse allergic re-
actions at home (eg, when and how to use medi-
cation, including adrenaline self-injector). The
ingestion, allergic reactions, and medications were
recorded in a diary. The severity of allergic symp-
toms for patients was graded using modified
anaphylactic symptom grading of the European
Academy of Allergy and Clinical Immunology
(EAACI),39 which could be easily modified using
Table S3. The medications prescribed were used
depending on the allergic reactions (eg, oral
antihistamine, oral steroid, beta 2 agonist
inhalation, or self-injectable adrenaline). All pa-
tients visited their respective hospital every 1–2
months for follow-up and treatment monitoring.
They were also provided with telephone contact
information for their hospital should allergic
symptoms occur. In this study, only OIT food-
related allergic symptoms were analyzed. Acci-
dental adverse reactions outside of the OIT,caused by other foods, medications, and allergic
complications (eg, rhinitis and asthma.) were
excluded from the analysis.
Measurement of IgE, IgG, and IgG4
In both groups, a blood test was performed
every 6 months. The range of antigen-sIgE was
0.35–100 (kUA/L). The level of antigen-sIgE was
measured using ImmunoCAP (Thermo Fisher Di-
agnostics K.K., Tokyo, Japan). Values  0.34 were
calculated as 0.15 and those  100 as 101. The
antigen-sIgG and antigen-sIgG4 were measured
using a residual serum and human ELISA kit
(Thermo Fisher Diagnostics K.K., Tokyo, Japan).
The range of sIgG was 2.0–200.0, and sIgG4 was
0.07–30.0 (mg/L). Values  2.0 were calculated as
1.0 and those  200.0 as 201.0; meanwhile
values  0.070 were calculated as 0.035
and  30.0 as 30.1.
Statistics
We hypothesized that 100%-dose OIT would
induce StU earlier than 25%-dose OIT. The
assumed StU rates for the 100%- and 25%-doses
were estimated to be 80% and 20%, respectively,
which was calculated by the outcome of a pre-
liminary outpatient OIT trial from 2009 to 2012 at
the Department of Pediatrics, Sagamihara National
Hospital (UMIN000011684, UMIN000011689). The
required number of sample size for the 100%- and
25%-dose groups was calculated as 15 cases each
for HE, CM, and wheat. ["Sampsi 0.8 0.2, p (0.8)”,
power ¼ 0.8, alpha ¼ 0.05 (two-sided), dropout
rate; 15%, using STATA 12, StataCorp LP, College
Station, TX, USA].
According to the primary and secondary out-
comes, comparisons of StU rates between the OIT
100%- and 25%-dose groups were conducted us-
ing Fisher's exact test. These outcomes were
analyzed by intention-to-treat and per-protocol set
analyses. We also defined the patients who dis-
continued OIT as allergic patients (worst-case
scenario). The influence of dropout cases was
analyzed by the tipping-point method.
Patient profile, age, antigen-sIgE level (for egg-
white, milk, and wheat), and allergic symptom
threshold were expressed as median values
(interquartile range) and compared between the
OIT groups using the Mann-Whitney U test.
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Allergic complications and the rate of past
anaphylaxis or infantile eczema were analyzed us-
ing Pearson's chi-squared test.
Allergic symptoms and medication rates during
OIT were also compared according to the other
secondary outcomes using Pearson's chi-squared
test. Changes in antigen-sIgE, -sIgG, and -sIgG4
during the follow-up period were compared using
the Wilcoxon signed-rank test with SPSS 24 (IBM
Corporation, Armonk, NY, USA). We made com-
plete 100 datasets of antigen-sIgE, -sIgG, and
-sIgG4 for the missing values through multiple
imputation (linear regression).RESULTS
Patient characteristics
A total of 101 patients consented to this study.
The 51 patients in the 100%-dose group (HE ¼ 26,
CM ¼ 13, wheat ¼ 12), and the 50 in the 25%-dose
group (HE ¼ 25, CM ¼ 13, wheat ¼ 12) were
examined by intention-to-treat analysis (Fig. 2). The
age groups were from early childhood to middleFig. 2 Patient diagram. OIT: oral immunotherapy, HE: hen's egg, CM:
patients who consented to OIT were randomized into two groups. OITschool age, and their past history rates of
anaphylaxis were approximately 30–69%
(Table 1). The number of allergic symptoms and
treatment at baseline OFC are expressed in
Table S4. No statistically significant differences in
baseline characteristics were observed between
the groups. However, the numbers of patients
assigned to the milk and wheat OIT were slightly
lower than the estimated sample size, ie, up to
15 patients for each group.Assessment of clinical response
Two methods were employed to analyze the
patients, namely intention-to-treat and per-
protocol set analysis. Using the intention-to-treat
analysis, all enrolled patients were analyzed and
the StU rate (%) for year one in the 100%- and 25%-
dose groups was 26.9 and 20.0 for HE, 7.7 and
15.4 for CM, and 50.0 and 16.7 for wheat (Fig. 3).
The rates for year 2 were 30.8 and 36.0, 7.7 and
23.1, 58.3 and 58.3 for HE, CM, and wheat,
respectively.
Using the per-protocol set analysis, only the
patients who complied with the OIT protocol werecow's milk, W: wheat. AE: adverse event. One-hundred and one
interruption occurred because of AE or loss to follow-up
HE 100% HE 25% CM 100% CM 25% W 100% W 25%
Subjects, (n) 26 25 13 13 12 12












Gender, (M/F) 16/10 11/14 7/6 11/2 8/4 8/4
Past history of infantile eczema,
(%)
50.0 60.0 38.5 46.2 75.0 75.0
BA, (%) 30.8 32.0 46.2 46.2 41.7 50.0
AD, (%) 53.8 64.0 61.5 53.8 75.0 66.7
AR, (%) 30.8 48.0 23.1 38.5 16.7 16.7
AC, (%) 15.4 12.0 7.7 23.1 8.3 0.0
Past history of An caused by HE,
CM or W, (%)
30.8 56.0 69.2 38.5 58.3 50.0




















Allergic symptom threshold at



















Table 1. Patient profiles at baseline. OIT: oral immunotherapy, HE: hen's egg, CM: cow's milk, W: wheat, y: years, M: male, F: female, BA: bronchial
asthma, AD: atopic dermatitis, AR: allergic rhinitis, AC: allergic conjunctivitis, An: anaphylaxis, Ew: egg-white, sIgE: specific immunoglobulin E, OFC: oral food
challenge. Patient age, antigen-sIgE, and allergic symptom threshold are expressed as median values (interquartile range). Comparisons were made using
Pearson's chi-squared test or the Mann-Whitney U testa. Regarding baseline patients' profiles, no statistically significant differences were observed for HE, CM
or W allergy between the 100%- and 25%-dose groups (p > 0.05)
Volume 13, No. 10, October 2020 7analyzed, and the StU rate (%) for year one in the
100%- and 25%-dose groups was 30.4 and. 27.8
for HE, 10.0 and 25.0 for CM, and 50.0 and 20.0 forFig. 3 Comparison of outcome between the 100%- and 25%-dose gro
(gray bar), ITT: intention-to-treat analysis, allergic (white bar). StU was
therapy. Y axis shows StU rate percentage. X axis shows the number o
year; (middle) milk allergy after OIT; (right) wheat allergy after OIT. The S
two groups was conducted by intention-to-treat analysis. p < 0.05 was
interval of population ratio is shown in the error-bar. Discontinued patwheat (Fig. S1). The number of patients for
desensitization and StU at year 1 are expressed
in Table S5. The StU rates for year 2 were 53.3ups. OIT: oral immunotherapy, StU: short-term unresponsiveness
measured by an oral food challenge test after 2-week cessation of
f patients. StU rate (%) for (left) egg allergy after OIT follow-up per
tU rate was rounded off. Comparison of OIT outcome between the
considered statistically significant (Fisher's exact test). Confidence
ients were considered allergic (worst-case scenario)
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http://doi.org/10.1016/j.waojou.2020.100463and 60.0, 20.0 and 37.5, and 77.8 and 70.0 for HE,
CM, and wheat, respectively.
There were no statistically significant differences
in StU rates between the OIT for the 100%- and
25%-dose groups as evaluated by each antigen
between year 1 and 2 by intention-to-treat and
per-protocol analyses (p > 0.05). In addition,
regarding the egg OIT outcome between year 1
and 2, the confidence interval distribution for their
population ratio appeared to overlap. Regarding
the milk OIT outcome, the confidence intervals did
not overlap at years 1 and 2. However, regarding
the wheat OIT outcome, the confidence intervals
did not overlap at year 1, yet appeared to do so at
year 2.
Assessment of allergic reactions and treatments
The ratio of total adverse reactions per total
ingestion times in the 25%-dose OIT group was
significantly lower than that in the 100%-dose OIT
group. Most of these allergic reactions during both
OITs were mild, with the most frequent adverse
reactions reportedly mild oral symptoms (Table 2).
The frequency of gastrointestinal symptoms,
including oral symptoms, during HE, CM, and
wheat OIT was higher in the 100%-dose group
than in the 25%-dose group. However, there was
no obvious trend in the frequency of other
organ-specific symptoms between these 2 groups.
Regarding the ratio of total treatments per total
ingestion during OIT, the rate in the 25%-dose OIT
group was significantly lower than that in the
100%-dose OIT group for wheat only. However, no
obvious trend was observed in the frequency of
using any medications between these two groups.
There were 5 cases of intramuscular adrenaline
injections used during OIT (CM in the 100%-dose
group ¼ 1, CM in the 25%-dose group ¼ 3, wheat
in the 25%-dose group ¼ 1), and 3 out of 5 cases
were defined as anaphylaxis: Grade 4 or 5 ac-
cording to the modified WAO grading system40
(CM in the 100%-dose group ¼ 1, CM in the
25%-dose group ¼ 1, wheat in the 25%-dose
group ¼ 1). Only one case of CM in the 25%-
dose group had reduced consciousness and was
classified as Grade 5 according to the grading
system of the World Allergy Organization (WAO).
However, no cases of anaphylactic shock,
respiratory failure or hypotension were observed.Importantly, the 3 anaphylactic cases and 1 non-
anaphylactic case out of 5, did not maintain the
1 h rest rule after OIT ingestion. The remaining 1
non-anaphylactic case developed acute enteritis
before ingestion. Furthermore, another patient
treated with adrenaline injection due to accidental
ingestion, was not related to OIT ingestion
(HE ¼ 1). However, this case's injection was
excluded from the analysis of this study.
Immunological changes
The levels of antigen-sIgE for egg-white, ovo-
mucoid, milk, casein, and wheat decreased signif-
icantly in the 100%- and 25%-dose groups at 12
months, compared to those at baseline (Fig. 4).
However, we did not observe a significant
association between the StU status and the
reduction of antigen-sIgE levels. With regards to
the omega-5 gliadin levels at 12 months, this was
significantly decreased in the 25%-dose group
only. The levels of antigen-sIgE for egg-white,
ovomucoid, milk, casein, wheat, and omega-5
gliadin in the 25%-dose group also significantly
decreased at 24 months. However, in the 100%-
dose group, the levels of antigen-sIgE for only
egg-white and ovomucoid significantly decreased
at 24 months. Furthermore, due to insufficient
sample size, we could not detect obvious changes
in antigen-sIgG and -sIgG4 levels in the 100%- and
25%-dose groups (Fig. S2 and S3). Integrated p
values of immunological changes by multiple
imputation for missing values are shown in
Table S6.
Discontinuation of OIT
A total of 22 and 17 patients discontinued OIT in
the 100%-dose group and 25%-dose group by the
2-year follow-up, respectively. Moreover, 10 out of
22 patients in the 100%-dose group, and another
14 out of 17 patients in the 25%-dose group dis-
continued their OIT owing to adverse events
(Fig. 2). The reasons for discontinuing OIT for the
10 and 14 patients in the 100%- and 25%-dose
groups were allergic symptoms (n ¼ 4 vs. 4),
children disliking the food (n ¼ 0 vs. 5), sudden
termination of hospital visits (n ¼ 6 vs. 2),
enrolling in a different OIT study (n ¼ 0 vs. 1),
worsening of atopic dermatitis (n ¼ 0 vs. 1), and














Subjects, (n) 26 25 13 13 12 12
Total times of OIT ingestion, (n) 9546 9623 4990 5260 5032 6239
Ratio of total adverse reactions per total
ingestion times, (%)
10.9 8.74a 15.4 10.3a 8.82 4.76a
Ratio of total treatments per total ingestion
times, (%)
2.13 1.98 2.34 2.22 2.50 1.15a
Severity of
symptoms, (%)
Grade 1 (mild) 10.2 7.57a 14.4 9.51a 7.63 3.77a
Grade 2 (moderate) 0.60a 1.14 0.86 0.67 0.97 0.96
Grade 3 (severe) 0.09 0.03 0.16 0.17 0.22 0.03a
Organ-specific
symptoms, (%)















Respiratory tract 0.90a 1.63 2.97 2.70 2.44 1.49a
Cardiovascular 0 0 0 0 0 0
Neurological 0.18 0.25 1.12 0.25 0.12 0.06
Treatments at
home, (%)
AH p.o. 2.10 1.92 1.94 2.17 2.34 1.14a
Steroid p.o. 0.16a 0.31 0.24 0.25 0.12 0.10
b2 agonist inhalation 0.05a 0.30 0.78 0.40a 0.42 0.05a
Adrenaline i.m. 0 0 0.02 0.06 0 0.02
Treatments at
hospital, (%)
Emergency visit 0.08 0.06 0.04a 0.23 0.02 0.08
AH i.v. or i.m. 0 0 0 0 0 0.02
Steroid i.v. 0.02 0 0.02 0.02 0 0.03
Table 2. Comparison of allergic reactions and treatment between 100%-dose and 25%-dose OIT. OIT: oral immunotherapy, HE: hen's egg, CM:
cow's milk, W: wheat, AH: antihistamine, p.o.: per oral, i.v.: intravascular, i.m.: intramuscular. Frequency of severity of symptoms, organ-specific symptoms and
treatments were calculated by number per total ingestion. Comparisons of HE, CM and W allergy between 100%-dose and 25%-dose OIT were conducted
using Pearson's chi-squared test a. p < 0.05 was considered statistically significant lower.
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period, 4 out of 9 hospitals chose not to extend the
study participation period from 12 to 24 months.
Hence, the patients in these 4 hospitals were lost
to follow-up at year 2, regardless of whether their
OIT could induce desensitization. Therefore, 11
patients in the 100%-dose group and one patient
in the 25%-dose group stopped their follow-up at
the first year. Other reasons for loss to follow-up
were moving away (n ¼ 1 vs. 0), acute infection
(n ¼ 0 vs. 1), and mother's pregnancy (n ¼ 0 vs. 1).DISCUSSION
The efficacy of OIT itself has been evaluated for
HE, CM, and peanut allergy in previous random-
ized control trials3–6,8,9,15,17–20,22,23,25,26,33,34 and
systematic reviews.41–46 In addition, a five-day
medium dose (2808 mg) of rush OIT in persistent
HE allergic children was recently found to desen-
sitize 94% of allergic patients with moderate to
mild adverse effects.47 Meanwhile, low dose OIT
seems to improve the safety of allergen ingestion
Fig. 4 Immunological changes in sIgE during OIT. OIT: oral immunotherapy, sIgE: specific immunoglobulin E. Antigen-sIgE (kUA/L) levels
for Left: egg-white (top) and ovomucoid (bottom) by each group during OIT, measured each 6 months; Middle: milk (top) and casein
(bottom); Right: wheat (top) and omega-5 gliadin (bottom). Data are expressed as median values (interquartile range). p < 0.05 was
considered statistically significant (horizontal line and *). Comparisons were conducted using the Wilcoxon signed-rank test (baseline;
0 month)
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http://doi.org/10.1016/j.waojou.2020.100463for severe allergic patients.22,29–31 Thus, the
adopted protocols, study designs, and endpoints
are often diverse, making it difficult to compare
their efficacies in terms of dose-dependent
outcome.48
In 2017, Vickery et al reported the similar
effectiveness of peanut OIT with the comparison of
10 times maintenance doses.33 In other previous
OIT reports for milk32 and wheat,34 no significant
differences in outcomes were observed when
compared to twice the maintenance dose.
However, a potential interference may occur with
combined SLIT for milk OIT,32 or it may be
difficult to achieve SU in highly allergic
patients.34 In addition, the optimal ingestion
dose, particularly for HE allergen during OIT, was
uncertain. To the best of our knowledge, our
preliminary, proof of concept study is the first
report on the dose-dependent OIT outcomes of
HE allergic patients. Our data may prove helpful to
inform the design of similar studies in larger pop-
ulations. Furthermore, the severity of allergy in the
patients of this study was moderate, with severe
anaphylactic patients being excluded to ensure
clear dose-differences in outcome. Moreover, our
definition of low dose was set lower than in pastreports;32,34 and no previous study has described
a comparison of more than 4 times larger dose-
differences in CM and wheat OIT outcomes using
such a patient population and focusing on the
lower dose.Dose-dependent outcome
In this study, a certain dose-dependent outcome
was not identified during HE, CM, and wheat OIT.
The effects of 25%-dose egg OIT might not be
inferior to those of the 100%-dose in terms of the
StU rate after a 2-year clinical follow-up. On the
contrary, the StU rates of milk OIT were lower than
that of egg and wheat, even at the 100%-dose.
Longer follow-up periods may be required to
compare dose dependency for milk OIT.
Regarding wheat OIT, the 100%-dose seemed to
induce StU at only year 1, which is earlier than that
induced by the 25%-dose. However, this difference
became negligible after the 2-year follow-up. Our
findings did not, therefore, indicate that similar
efficacy is obtained with a low and target dose OIT
for milk and wheat. To examine the influence of
dropout cases, tipping-point analysis was con-
ducted, and the results are shown in Fig. S4. There
was less influence of dropout cases on the primary
Volume 13, No. 10, October 2020 11outcome at year 1. In addition, it was difficult to
compare our outcome to that of past OIT studies
as we excluded patients who had been treated
with adrenaline injection at the baseline OFC for
safety. There might also be a slight placebo bias
owing to the open-labeled nature of this study.Feasibility of 25%-dose OIT
Although it may be easier for children to ingest
low doses of OIT, particularly peanut,49
continuation of HE, CM, and wheat OIT for
children is nevertheless stress-laden if the therapy
has to be continued over a long period, even if the
maintenance dose is as small as 25% of OIT. To
further reduce stress during OIT, very low doses
may be required, as used in previous studies.22,29–
31 This observation implies the need for careful
consideration of indication for OIT, maintenance
dose, and treatment period for this class of
patients. Such considerations may, however,
change in the future with the emergence of
individualized therapy that can stratify patients by
the severity of their allergies to provide
enhanced treatment safety, convenience, and
efficacy.50Adverse reactions of lower dose OIT
In this study, 49 out of 101 (48.5%) OIT patients
had a past history of anaphylaxis, although most
adverse allergic symptoms that occurred during
OIT were mild. In addition, the rate of total allergic
symptoms in the 25%-dose group was lower than
that in the 100%-dose group, apart from the
adrenaline injection frequency. Our results (25%-
dose OIT) and those of Vickery et al.33 (10%-dose
OIT) suggest that low dosages might decrease the
rate of adverse allergic symptoms. However, 50%-
dose OIT32,34 was unable to significantly decrease
the adverse symptom rate. Thus, to meaningfully
decrease adverse symptoms, a low dose OIT of
at least 25% may be necessary.
Moreover, several cases of adrenaline injections
occurred during milk and wheat OIT. The co-
factors of anaphylaxis were exercising, going out,
or bathing within 1 h of OIT ingestion. Although
the patients were advised on the “rest rule” during
OIT, some parents became careless, suggesting
the need to provide more comprehensiveexplanations to patients and their legal guardians
in relation to the importance of strictly adhering to
the rules/guidelines associated with OIT, espe-
cially for milk and wheat OIT. Regardless, the 25%-
dose OIT significantly reduced the mild allergic
symptoms. However, it was difficult to conclude
whether the safety improved in the 25% group
compared to the 100% group, since four adrena-
line injections for milk and wheat reactions were
administered in the 25% group. Further reduction
of the maintenance dose may be necessary to
reduce the risk of moderate or severe symptoms
caused by milk and wheat OIT.Immunological changes
In this study, low doses of OIT induced certain
reduction in the levels of antigen-sIgE against their
causative antigens at 12 months. Moreover, the
25%-maintenance dose appeared to induce
similar levels of causative antigen-sIgE at 12
months as that induced by the larger doses, as
supported by immunological changes. However,
antigen-sIgG and -sIgG4 could be measured only
in few cases owing to insufficient residual serum.Limitations
There are a number of limitations noted in the
current study. First, most traditional OIT studies
measured typical SU up to 4–10 weeks after
cessation of therapy. However, in this study, the
primary outcome was StU, which was only
measured at 2 weeks after cessation of therapy.
This two-week avoidance was used to evaluate
clinical efficacy of OIT in previous
reports.11,12,14,29–31 However, our StU definition
was unlikely to distinguish desensitization from
typical SU. If the cessation period was longer,
different results for OIT outcome might have
been obtained. However, in terms of efficacy
comparison between the 100%-dose and 25%-
dose OIT, we considered that StU might have
slightly affected the primary endpoint. Moreover,
HE, CM, and wheat could be eaten regularly as
diet, and thus 2 weeks of cessation was clinically
appropriate to suspend ingestion owing to acute
infection, travel, or other reasons during OIT.
Second, the follow-up period of this study was
extended from 1 year to 2 years (trial registry was
fixed at February 2014), and owing to the lack of
12 Ogura et al. World Allergy Organization Journal (2020) 13:100463
http://doi.org/10.1016/j.waojou.2020.100463case follow-up, or residual serum at year 2, there
were some missing values of immunological
changes, particularly for the antigens specific for
IgG and IgG4 in the OIT group.
In addition, we aimed to investigate the efficacy
of OIT compared to the natural course without
therapy in terms of the secondary outcome. How-
ever, there were not enough patients in the control
group for valid statistical analysis, as many
preferred to participate in the trial in the OIT
groups. Moreover, it was difficult to keep patients
in the control group for 1–2 years, as they all had
national insurance coverage and were able to
choose other allergists freely and for a low price in
Japan. Only 6 patients (HE ¼ 3, CM ¼ 2, wheat ¼ 1)
who did not consent to OIT were enrolled in the
control group, none of whom attained tolerance
for the StU target dose during the 2-year follow-up.
Therefore, we could not compare OIT efficacy to
the natural outgrowing tolerance.CONCLUSIONS
This investigation was unable to show a statisti-
cally significant difference between the 100%-dose
group and the reduced 25%-dose group. Owing
to insufficient statistical power, particularly for milk
and wheat, follow-up studies using a larger study
population will be required to replicate and vali-
date our finding that reducing the maintenance
dose of OIT may exert equivalent therapeutic effi-
cacy as that achieved by the target dose of OIT.
However, limited to the results on egg OIT, this
study may have suggested that the 25%-dose was
similar to the 100%-dose in terms of clinical
effectiveness after 2 years of follow-up. Reducing
the maintenance dose for eggs, milk, and wheat
may effectively lower the symptoms associated
with their consumption compared to the target OIT
dose. However, the 25%-dose group for milk and
wheat required a few adrenaline injections. Further
reduction of the maintenance dose may be
necessary to reduce the risk of anaphylaxis,
particularly for the milk and wheat OIT. Further-
more, patient compliance, stress inflicted by
eating, and quality of life associated with StU
needs to be compared among the 100%-, 25%-,
and further reduction-dose OIT.Abbreviations
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